<scp>MAb NJ001</scp> inhibits lung adenocarcinoma invasiveness by directly regulating <scp>TIMP</scp>‐3 promoter activity via <scp>FOXP1</scp> binding sites

Li, Zhuoshi; Luo, Ying; Zhang, Shichang; Xu, Jian; Zhang, Jiexin; Ju, Huanyu; Liu, Jingping; Zhang, Lixia; Zhang, Yan; Wu, Lei; Xie, Erfu; Xu, Ting; Pan, Shiyang

doi:10.1111/1759-7714.13593

Cited by 5 publications

(3 citation statements)

References 34 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, SP70 is involved in regulating gene expression related to migration and invasion of tumor cells. SP70 blocked could upregulate the expression of tissue inhibitor of metalloproteinase 3 (TIMP3) ( 40 ). The expression and involvement of TIMP3 in regulating the growth, migration and invasion of HCC and other tumors have been determined in several studies ( 41 – 43 ).…”

Section: Discussionmentioning

confidence: 99%

SP70 is a novel biomarker of hepatocellular carcinoma

et al. 2023

Self Cite

View full text Add to dashboard Cite

BackgroundTumor-specific protein 70 (SP70) was identified as a new biomarker associated with the proliferation and invasion of cancer cells. This study aimed to investigate the expression of SP70 in hepatocellular carcinoma (HCC) and assess its clinical value in the diagnosis and prediction of early HCC recurrence.MethodsA total of 1049 subjects from the First Affiliated Hospital of Nanjing Medical University were recruited in this study. Serum SP70, alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence II (PIVKA-II) were measured. The diagnostic performance for HCC was obtained using the receiver operating characteristic (ROC) curve, and recurrence-free survival (RFS) was calculated using the Kaplan–Meier method. Univariate and multivariate analyses were performed to identify predictive factors of RFS.ResultsSP70 was highly expressed in HCC cells and HCC tissue. Serum SP70 levels in the HCC group were significantly higher than in the benign liver diseases group and healthy control group (P<0.001). SP70 combined with AFP showed the best diagnostic performance (AUC=0.909, 95%CI [confidence interval]=0.890–0.929). Kaplan–Meier analysis revealed that patients with high SP70 levels had shorter median RFS than those with low SP70 levels (P=0.003). In addition, high SP70 levels were significantly associated with shorter RFS (P=0.037) in the AFP-negative subgroup. Univariate and multivariate analyses confirmed that preoperative serum SP70 level, serum AFP, tumor diameter and microvascular invasion were independent prognostic factors of RFS.ConclusionSP70 is a promising biomarker in diagnosing HCC. High preoperative serum SP70 level is associated with an increased risk of early relapse and could be used as a valuable marker to predict early recurrence of HCC after resection.

show abstract

Section: Discussionmentioning

confidence: 99%

SP70 is a novel biomarker of hepatocellular carcinoma

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…SP70 is an antigen of non-small-cell lung cancer (NSCLC) specifically identified by the McAb NJ001 [ 13 , 14 ]. It has been produced by immunizing mice with human SPC-A1 lung adenocarcinoma live-cell antigen [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

SP70 is a potential biomarker to identify gastric fundic gland neoplasms

et al. 2022

View full text Add to dashboard Cite

Background Gastric neoplasms with fundic gland differentiation include oxyntic gland adenomas (OGAs) and gastric adenocarcinomas of fundic gland type (GA-FGs). Due to their well-differentiated and similar morphology with normal fundic glands, it is usually challenging to identify these lesions in pathological diagnosis, especially in biopsy specimens. This study aims to explore and verify the potential role of a newly developed monoclonal antibody (McAb) NJ001 (SP70) in differentiating fundic neoplasms from non-neoplastic fundic gland lesions. Methods Twenty-three cases of histological confirmed gastric fundic gland neoplasms were obtained, including 12 cases of OGAs and 11 of GA-FGs. Fifty cases of fundic gland polyps (FGPs) were taken as the control group. Six cases of well-differentiated gastric neuroendocrine tumors (NETs) (easily misdiagnosed) were also obtained. Key clinicopathological information was collected. SP70 immunostaining was performed (with para-tumor normal fundic glands as internal control). The positive intensity and staining pattern of SP70 were analyzed and compared. Results In normal gastric mucosa, SP70 was strongly and diffusely stained on the cytoplasm in fundic glands, but not in the foveolar epithelium. Therefore, a zonal distribution of SP70 was observed in normal mucosa. FGPs (50/50, 100%) shared a similar expression pattern with normal fundic glands. In fundic gland neoplasms, a significant down-expression of SP70 was observed in both OGAs and GA-FGs. The positive rate of SP70 in fundic gland neoplasms (6/23, 26.1%) was significantly lower than that in FGPs (100%) (P<0.0001). There was no difference in SP70 expression between OGAs (3/12, 25.0%) and GA-FGs (3/11, 27.2%) group (P>0.05). In these 6 NET cases, SP70 was weak to moderate intensity in the majority of tumor cells (with a different expression pattern). Conclusion Down-expression of SP70 is a specific feature to fundic gland neoplasms including OGAs and GA-FGs. Therefore, SP70 can serve as a potential biomarker in the identification and differential diagnosis of fundic gland neoplasms.

show abstract

“…Newly developed speci c IHC biomarkers that can distinguish fundic gland neoplasms from non-neoplastic lesions are needed to improve the diagnostic di culties, especially in cases with atypical morphology and in biopsy specimens with limited tissue. SP70 is an antigen of non-small-cell lung cancer (NSCLC) speci cally identi ed by the McAb NJ001 [14,15]. It has been successfully produced by immunizing mice with human SPC-A1 lung adencarcinoma live cell antigen [15].…”

Section: Introductionmentioning

confidence: 99%

SP70 is a Potential Biomarker to Identify Gastric Fundic Gland Neoplasms

Huang

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Gastric neoplasms with fundic gland differentiation include oxyntic gland adenomas (OGAs) and gastric adenocarcinomas of fundic gland type (GA-FGs). Due to their extremely well differentiation and morphological similarity to normal fundic glands, it is usually challenging to identify these lesions in pathological diagnosis, especially in biopsy specimens. This study aims to explore and verify the potential role of a newly developed monoclonal antibody (McAb) NJ001 (SP70) in differentiating fundic neoplasms from non-neoplastic fundic gland lesions. Methods Twenty-three cases of histological confirmed gastric fundic gland neoplasms were obtained, including 12 cases of OGAs and 11 of GA-FGs. Fifty cases of fundic gland polyps (FGPs) were also obtained in the control group. Key clinicopathological information was collected. SP70 immunostaining was performed, the intensity, as well as the staining pattern was analyzed and compared. The para-tumor normal fundic glands were used as internal control.Results In normal gastric mucosa, SP70 was strongly and diffusely stained on the cytoplasm in fundic glands, but not in foveolar epithelium. Therefore, a zonal distribution of SP70 was observed in normal mucosa. FGPs (50/50, 100%) shared a similar expression pattern with normal fundic glands. In fundic gland neoplasms, a significant down-expression of SP70 was observed in both OGAs and GA-FGs. The positive rate of SP70 in fundic gland neoplasms (6/23, 26.1%) was significantly lower than that in FGPs (100%) (P＜0.0001). There was no difference of SP70 positivity between OGAs (3/12, 25.0%) and GA-FGs (3/11, 27.2%) group (P>0.05).Conclusion Down-expression of SP70 is a specific feature to fundic gland neoplasms including OGAs and GA-FGs. Therefore, SP70 can serve as a potential biomarker in the identification and differential diagnosis of fundic gland neoplasms.

show abstract

MAb NJ001 inhibits lung adenocarcinoma invasiveness by directly regulating TIMP‐3 promoter activity via FOXP1 binding sites

Cited by 5 publications

References 34 publications

SP70 is a novel biomarker of hepatocellular carcinoma

SP70 is a novel biomarker of hepatocellular carcinoma

SP70 is a potential biomarker to identify gastric fundic gland neoplasms

SP70 is a Potential Biomarker to Identify Gastric Fundic Gland Neoplasms

Contact Info

Product

Resources

About